The Board of Directors of Sanofi India Limited, at its meeting held today, has approved a scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013, to demerge its Consumer Healthcare Business from the Demerged Company into its wholly-owned subsidiary Sanofi Consumer Healthcare India Limited (currently under the process of incorporation) ('SCHIL /Resulting Company'). The detailed disclosures pertaining to the Scheme are captured in the attachment. Kindly refer to the attached letter for details. (As per BSE Announcement Dated on 23/09/2023) We would like to inform you that the Hon''ble NCLT, Mumbai Bench vide order dated 24th November 2023 has rectified the error by fixing the appointed date of the scheme as to 1st June 2023. (As Per BSE Announcement Dated on 29.11.2023) Judicial pronouncement by the Hon''ble National Company Law Tribunal, Mumbai bench, approving the Scheme of Arrangement ('Scheme') between Sanofi India Limited and Sanofi Consumer Healthcare India Limited ('NCLT Order') (As per BSE Announcement Dated on 09/05/2024) Effectiveness of the Scheme of Arrangement between Sanofi India Limited and Sanofi Consumer Healthcare India Limited (As Per BSE Announcement Dated on: 01/06/2024) In accordance with the provisions of the Scheme of Arrangement between Sanofi India Limited ('Demerged Company') and Sanofi Consumer Healthcare India Limited ('Resulting Company') and their respective shareholders under Section 230-232 of the Companies Act, 2013, which was sanctioned by the Hon'ble National Company Law Tribunal, Mumbai Bench, through its order dated 7th May 2024, and in adherence to Regulation 42 of the SEBI Listing Regulations, we wish to inform you that, Thursday, 13th June 2024, has been fixed as the Record Date' for the purpose of ascertaining the shareholders of the Demerged Company who will be entitled to receive fully paid-up equity shares of Rs 10/- each of the Resulting Company pursuant to the Scheme of Arrangement. Accordingly, 1 equity share of the face value of Rs. 10/- each fully paid-up of the Resulting Company shall be issued and allotted for every 1 equity share of face value of Rs 10/- each fully paid-up held by equity shareholders of the Demerged Company. The equity shares proposed to be allotted by the Resulting Company are proposed to be listed with the National Stock Exchange of India Limited and the BSE Limited subject to the applicable regulations and the necessary regulatory approvals. We request you to take the above on record and treat the same as compliance under the applicable provisions of the SEBI Listing Regulations. (As Per BSE Announcement Dated on 03.06.2024) Trading Members of the Exchange are hereby informed that, pursuant to the Scheme of Arrangement among Sanofi India Limited and Sanofi Consumer Healthcare India Limited as approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, SANOFI INDIA LIMITED has fixed Record Date for the purpose of determining the entitlement of the shareholders of the Company, as per details given below: - COMPANY NAME CODE SANOFI INDIA LIMITED (500674) RECORD DATE 13/06/2024 PURPOSE As per Scheme of Arrangement sanctioned by the Hon'ble National Company Law Tribunal, Mumbai Bench, inter alia, between, SANOFI INDIA LIMITED, (Demerged Company) and Sanofi Consumer Healthcare India Limited (Resulting Company) and their Respective Shareholders and Creditors; The Scheme of Arrangement proposes the Demerger of Consumer Healthcare business of the Company to Sanofi Consumer Healthcare India Limited (Resulting Company) ; Upon the Scheme coming into effect and In consideration of the Demerger of the Consumer Healthcare business of the Company to Sanofi Consumer Healthcare India Limited (Resulting Company); Sanofi Consumer Healthcare India Limited (Resulting Company) shall issue and allot Equity Shares to the Shareholders of Sanofi India Limited in the following proportion:- 'Each Member of Sanofi India Limited holding One (1) Fully Paid-up Equity Share in Sanofi India Limited as on the Record Date shall in respect of every One (1) Fully Paid-Up Equity Share of Rs.10/- each held in Sanofi India Limited be entitled to receive One (1) Fully Paid-Up Equity Share of Rs.10/- each of Sanofi Consumer Healthcare India Limited EX-ENTITLEMENT FROM DATE & SETT. NO. 13/06/2024 DR-652/2024-2025 Note: (1) Pursuant to SEBI Circular No. SEBI/Cir/ISD/1/2010 dated November 2, 2010, Trading members are hereby informed that the trading in the Equity Shares of the aforesaid Company shall be transferred from A' group to T' Froup w.e.f. 13th June, 2024, and (2) Pursuant to SEBI Circular No. CIR/MRD/DP/01/2012 dated January 20, 2012, the aforesaid scrip shall be a part of Call Auction in Pre-open Session (Special Pre- open Session (SPOS)) on 13th June, 2024. For further information on SPOS, the trading members are requested to refer to the Exchanges notice no. 20120216-29 dated February 16, 2012 on Enabling Special Pre-open Session. Subject to compliance with requisite formalities, the Equity Shares of the Resulting Company i.e. Sanofi Consumer Healthcare India Limited will be listed on BSE Limited. (As Per BSE Notice Dated on 11.06.2024) Allotment of shares pursuant to the Scheme of Arrangement between Company and Sanofi Consumer Healthcare India Limited (As per BSE Announcement Dated on 18/06/2024) Please find enclosed communication for the attention of the shareholders of the Company for Apportionment of Cost of Acquisition of Equity Shares of Sanofi India Limited and Sanofi Consumer Healthcare India Limited pursuant to the Scheme. Read less.. (As Per BSE Announcement Dated on 12.07.2024)